DA Davidson Has Negative Outlook for USNA Q1 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at DA Davidson decreased their Q1 2025 earnings per share estimates for shares of USANA Health Sciences in a research report issued on Thursday, February 27th. DA Davidson analyst C. Xue now expects that the company will earn $0.76 per share for the quarter, down from their previous forecast of $0.83. DA Davidson has a “Neutral” rating and a $36.00 price objective on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. DA Davidson also issued estimates for USANA Health Sciences’ Q1 2025 earnings at $0.76 EPS, FY2025 earnings at $2.38 EPS, FY2025 earnings at $2.38 EPS and FY2026 earnings at $2.59 EPS.

Other research analysts have also recently issued reports about the company. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Sidoti cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th.

USANA Health Sciences Stock Performance

NYSE:USNA opened at $29.55 on Friday. The stock has a 50-day simple moving average of $33.50 and a 200-day simple moving average of $36.56. The stock has a market cap of $563.22 million, a P/E ratio of 10.44, a P/E/G ratio of 0.93 and a beta of 0.87. USANA Health Sciences has a 1 year low of $27.71 and a 1 year high of $50.32.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Institutional Trading of USANA Health Sciences

A number of large investors have recently made changes to their positions in USNA. Creative Planning acquired a new stake in shares of USANA Health Sciences in the 3rd quarter valued at about $394,000. Allspring Global Investments Holdings LLC boosted its position in shares of USANA Health Sciences by 14,068.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock valued at $1,472,000 after purchasing an additional 38,547 shares during the period. Harbor Capital Advisors Inc. boosted its position in shares of USANA Health Sciences by 44.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 8,859 shares of the company’s stock valued at $336,000 after purchasing an additional 2,713 shares during the period. KBC Group NV boosted its position in shares of USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares during the period. Finally, Royce & Associates LP boosted its position in shares of USANA Health Sciences by 22.2% in the 3rd quarter. Royce & Associates LP now owns 33,143 shares of the company’s stock valued at $1,257,000 after purchasing an additional 6,031 shares during the period. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.